68,349 Shares in 4D Molecular Therapeutics, Inc. $FDMT Purchased by Man Group plc

Key Points

• Man Group plc acquired 68,349 shares of 4D Molecular Therapeutics in the second quarter, valued at approximately $909,000. Institutional investors collectively own 99.27% of FDMT.
• Analyst sentiment remains broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $29.62, although some firms maintain sell or hold ratings.
• FDMT reported a quarterly loss of $1.04 per share, slightly worse than estimates, while revenue of $3.78 million exceeded expectations. Insiders sold 199,158 shares worth $2.23 million during the latest quarter.

Man Group plc acquired a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 68,349 shares of the company's stock, valued at approximately $909,000. Man Group plc owned approximately 0.13% of 4D Molecular Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently modified their holdings of the company. Jupiter Topco LLC purchased a new stake in 4D Molecular Therapeutics during the second quarter worth about $76,466,000. BlackRock Inc. bought a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at approximately $60,463,000. Janus Henderson Group PLC increased its stake in shares of 4D Molecular Therapeutics by 164.4% during the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company's stock worth $34,726,000 after purchasing an additional 2,882,508 shares during the last quarter. Trails Edge Capital Partners LP bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $29,631,296. Finally, State Street Corp raised its holdings in shares of 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company's stock worth $20,167,000 after purchasing an additional 1,785,106 shares during the period. Institutional investors own 99.27% of the company's stock.

Insider Activity at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 9,810 shares of the company's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider owned 8,617 shares of the company's stock, valued at approximately $103,404. This represents a 53.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David Kirn sold 12,415 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $10.05, for a total value of $124,770.75. Following the completion of the sale, the insider owned 871,737 shares in the company, valued at $8,760,956.85. This trade represents a 1.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 199,158 shares of company stock worth $2,229,161 over the last quarter. Corporate insiders own 7.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on FDMT. B. Riley Financial restated a "buy" rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. HC Wainwright reiterated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. The Goldman Sachs Group reissued a "buy" rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Finally, Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, 4D Molecular Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $29.62.

4D Molecular Therapeutics Stock Down 1.6%

FDMT stock opened at $14.70 on Friday. The stock has a 50-day simple moving average of $12.47 and a two-hundred day simple moving average of $10.49. 4D Molecular Therapeutics, Inc. has a twelve month low of $6.09 and a twelve month high of $16.93. The firm has a market capitalization of $812.03 million, a PE ratio of -5.59 and a beta of 2.74. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). The firm had revenue of $3.78 million during the quarter, compared to analysts' expectations of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. On average, equities analysts predict that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source